An infusion of seed capital will help finance a Lenexa biomedical company’s efforts to launch clinical trials for one of its new drugs and help improve two others.

VasoGenix, located in the Enterprise Center of Johnson County in Lenexa, received $350,000 from five area funds.

The company intends to use the money to help initiate clinical testing during the next six months for Vasonex, which treats angioplasty-induced complications.

“We’ll be filing an investigational new drug application with the FDA and manufacturing the drug supplies needed for the clinical trials for Vasonex,” said Gary Yewey, the company’s president and chief executive officer.

The financing also will help the company continue working with Kansas University’s Higuchi Biosciences Center to boost the effectiveness of Valynax and Vytorex, the company’s formulations for treating sexual dysfunctions.

In moving his company last year from Denver, Yewey said he was impressed by the Kansas City area’s pharmaceutical network and its growing infrastructure to support life-sciences research and commercialization.

The Precede Fund, of Kansas City, Kan., invested $100,000 in VasoGenix. Two funds each invested $75,000: KTEC Holdings, managed by Kansas Technology Enterprise Corp. in Topeka, and Bi-State Investment Group, Lenexa.

Investing $50,000 each were Wichita Technology Holdings, Wichita, and Prairie Investments for Technology Advancement, Lenexa.

“By combining these five regional funds, we were able to provide needed capital to an emerging company with a bright future,” said Matthew McClorey, a KTEC vice president and board member of the Lawrence Technology Assn.